Canada markets close in 5 hours 50 minutes

Sanofi (SNY)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
48.89+0.47 (+0.97%)
As of 10:10AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close48.42
Open48.60
Bid48.83 x 200
Ask48.95 x 100
Day's Range48.59 - 48.91
52 Week Range42.63 - 55.72
Volume139,487
Avg. Volume1,976,169
Market Cap122.277B
Beta (5Y Monthly)0.44
PE Ratio (TTM)24.82
EPS (TTM)1.97
Earnings DateJul 25, 2024
Forward Dividend & Yield2.04 (4.21%)
Ex-Dividend DateMay 09, 2024
1y Target Est59.90
  • GlobeNewswire

    Press Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration

    Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration Paris, New York, N.Y., and San Francisco, CA, May 21, 2024. Sanofi, Formation Bio and OpenAI are collaborating to build AI-powered software to accelerate drug development and bring new medicines to patients more efficiently. The three teams will bring together data, software and tuned models to develop custom, purpose-built solutions across the drug development lifecycle. This represents a first collaboration of its kind w

  • GlobeNewswire

    Sanofi: Information concerning the total number of voting rights and shares - April 2024

    Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of 2,529,599,938 €Registered office : 46, avenue de la Grande Armée - 75017 Paris - FranceRegistered at the Paris Commercial and Companies Regi

  • GlobeNewswire

    Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM

    Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM NOTUS results confirm landmark data from the phase 3 BOREAS study and show Dupixent significantly reduced exacerbations by 34% and improved lung function, compared to placebo, in uncontrolled chronic obstructive pulmonary disease (COPD) with evidence of type 2 inflammationData support the potential of Dupixent as the first new treatment approach in more than a decade and first-ever targ